NICE Rejects Javlor, But Could Products For Unmet Clinical Needs Be Rethought?
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K. cost watchdog rejects Pierre Fabre's Javlor even though it extended the survival of patients with metastatic bladder cancer.